NCT06167109 NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma
| NCT ID | NCT06167109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chongqing University Cancer Hospital |
| Condition | Nasopharyngeal Carcinoma by AJCC V8 Stage |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-10-20 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-10-20 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single-center clinical trial in eccentric nasopharyngeal carcinoma (NPC) patients. The aim of this study is to evaluate the efficacy and safety of NBI combined with MRI-guided optimized CTV compared with conventional CTV, and to compare the radiotherapy-related adverse events and quality of life between the two groups.
Eligibility Criteria
Inclusion Criteria: 1. Males and females ≥18 years of age; 2. ECOG Performance Status 0,1 or 2; 3. Pathologically diagnosed as nasopharyngeal carcinoma; 4. Pretreatment nasopharynx and neck MRI imaging; 5. Nasopharyngeal suspected lesions were examined by NBI endoscopy; 6. Meeting the definition of eccentric NPC with ipsilateral (affected side) staging of T1-4 and contralateral (healthy side) staging of T0; 7. Patients evaluated without contraindications to radiotherapy; 8. Voluntary participation in clinical research, and signed informed consent. Exclusion Criteria: 1. Patients who did not successfully undergo all three examinations (MRI, NBI, and endoscopic biopsy); 2. Other rare pathological types, such as adenocarcinoma; 3. Patients with tumor invasion of the clivus; 4. Patients whose contralateral retropharyngeal lymph nodes met the diagnostic criteria; 5. Invasion of paranasal sinuses (except simple sphenoid invasion).
Contact & Investigator
Ying Wang, Ph.D, M.D.
PRINCIPAL INVESTIGATOR
Chongqing University Cancer Hospital
Frequently Asked Questions
Who can join the NCT06167109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasopharyngeal Carcinoma by AJCC V8 Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06167109 currently recruiting?
Yes, NCT06167109 is actively recruiting participants. Contact the research team at 38664816@qq.com for enrollment information.
Where is the NCT06167109 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06167109 clinical trial?
NCT06167109 is sponsored by Chongqing University Cancer Hospital. The principal investigator is Ying Wang, Ph.D, M.D. at Chongqing University Cancer Hospital. The trial plans to enroll 60 participants.